Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade

BACKGROUND: Despite the survival benefits observed with immune checkpoint blockade (ICB) treatment—programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1), many patients with cancer have not benefited from these agents because of impaired antigen presentation and other resistance mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lijun, Li, Bingyu, Pi, Chenyu, Zhu, Zhaohua, Tao, Fei, Xie, Kun, Feng, Yan, Xu, Xiaoqing, Yin, Yanxin, Gu, Hua, Fang, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723960/
https://www.ncbi.nlm.nih.gov/pubmed/36460336
http://dx.doi.org/10.1136/jitc-2022-005447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723960/
https://www.ncbi.nlm.nih.gov/pubmed/36460336
http://dx.doi.org/10.1136/jitc-2022-005447

Ejemplares similares